China-based vaccines developer Sinovac Biotech (Nasdaq: SVA) responded to a recent report regarding the allegations raised in a research report by Geoinvesting.
It is suggested that recently disclosed documents show Sinovac’s chief executive bribed a member of the Chinese Food and Drug Administration (CFDA) to assist its drug clinical trial and approval. Geoinvesting tweeted: “We believe this revelation jeopardizes Sinovac’s two outstanding go private offers and could also impact future CFDA approvals and its cash flow.”
Sinovac's Audit Committee has authorized the commencement of an internal investigation into the allegations made in the report. The Audit Committee has engaged Latham & Watkins as independent counsel to assist with the investigation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze